10-Q: DT Cloud Acquisition Corp Reports Net Income of $1.63 Million for Nine Months Ended September 30, 2024, Amidst Business Combination Efforts

DT Cloud Acquisition Corporation reported a net income of $1.63 million for the nine months ended September 30, 2024, while actively pursuing a business combination with Shanghai Maius Pharmaceutical Technology Co., LTD.

Summary

• DT Cloud Acquisition Corporation, a blank check company, reported a net income of $1.63 million for the nine months ended September 30, 2024, compared to a net loss of $5,257 for the same period in 2023.
• The company's total assets stood at $71.72 million, including $71.52 million held in a trust account, as of September 30, 2024.
• The company consummated its initial public offering (IPO) on February 23, 2024, raising gross proceeds of $69 million from the sale of 6.9 million units and $2.345 million from a private placement.
• The company has entered into a business combination agreement with Shanghai Maius Pharmaceutical Technology Co., LTD, with a deadline of February 23, 2025, to complete the transaction, which can be extended to February 23, 2026, with additional funding.
• The company's financial statements indicate a going concern uncertainty due to the requirement to complete a business combination by the deadline or face liquidation.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company has achieved a net income and secured a business combination agreement, the going concern uncertainty, material weaknesses in internal controls, and the need for additional financing raise significant concerns. The sentiment is therefore cautiously negative.

Positives

• The company successfully completed its IPO and private placement, raising significant capital.
• The company has secured a business combination agreement with a target company.
• The company has generated a net income of $1.63 million for the nine months ended September 30, 2024.
• The company has a substantial amount of assets held in trust, which can be used for the business combination.

Negatives

• The company faces a going concern uncertainty due to the requirement to complete a business combination by a specific deadline.
• The company's disclosure controls and procedures were deemed not effective due to material weaknesses in internal control over financial reporting.
• The company has incurred significant formation and operating costs of $538,462 for the nine months ended September 30, 2024.
• The company has a limited cash balance of $167,526 outside of the trust account.

Risks

• The company's ability to continue as a going concern is dependent on completing a business combination by February 23, 2025, or February 23, 2026, if extended.
• The company's disclosure controls and procedures were not effective due to material weaknesses in internal control over financial reporting.
• The business combination is subject to various conditions, including shareholder approvals and regulatory clearances, which may not be obtained.
• The company may not be able to secure PIPE financing as contemplated in the business combination agreement.
• The business combination may be taxable to U.S. holders if it does not qualify as an exchange under Section 351 of the Code.
• The company may not have sufficient funds to consummate the business combination and may need to borrow funds or liquidate.
• The company is exposed to risks associated with economic uncertainty, capital market disruptions, and geopolitical instability.
• The company depends on a variety of U.S. and multi-national financial institutions to provide banking services, and the default or failure of one or more of these institutions may adversely affect the company's business and financial condition.

Future Outlook

The company is focused on completing its business combination with Shanghai Maius Pharmaceutical Technology Co., LTD by the deadline of February 23, 2025, or February 23, 2026, if extended. The company's future is dependent on the successful completion of this transaction.

Management Comments

• Management has determined that if the Company is unsuccessful in consummating an initial business combination within the prescribed period of time from the closing of the IPO, the requirement that the Company cease all operations, redeem the public shares and thereafter liquidate and dissolve raises substantial doubt about the ability to continue as a going concern.
• Management is currently assessing to evaluate the impact of the COVID-19 pandemic and has concluded that while it is reasonably possible that the virus could have a negative effect on the Companys financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of these unaudited financial statements.

Industry Context

The company operates in the special purpose acquisition company (SPAC) sector, which has seen increased activity in recent years. The company's focus on a business combination in the biopharmaceutical industry aligns with current trends in the market.

Comparison to Industry Standards

• The company's financial performance is typical for a SPAC in its pre-business combination phase, with minimal operating revenue and reliance on interest income from the trust account.
• The company's focus on a business combination with a biopharmaceutical company is consistent with the trend of SPACs targeting high-growth sectors.
• The company's timeline for completing a business combination is within the typical range for SPACs, but the going concern uncertainty highlights the risks associated with these types of entities.
• Compared to other SPACs, the company's financial position is relatively strong with a substantial amount of assets held in trust, but the limited cash outside of the trust account is a concern.
• The company's disclosure controls and procedures issues are not uncommon for smaller reporting companies, but they need to be addressed to ensure accurate financial reporting.

Related Party Transactions

• The company has a promissory note with the sponsor, which is non-interest-bearing and payable on the consummation of the initial business combination or converted upon consummation of the business combination into additional private units at a price of $10.00 per unit.
• The company has a temporary advance from the sponsor, which is unsecured, interest-free, and has no fixed terms of repayment.
• The company has an administrative services agreement with an affiliate of the sponsor, where the company pays $10,000 per month for services.
• The sponsor, officers, directors, or their affiliates may loan the company funds as may be required (Working Capital Loan) to fund working capital deficiencies or finance transaction costs in connection with an initial business combination.

Stakeholder Impact

• Shareholders face the risk of losing their investment if the business combination is not completed by the deadline.
• Shareholders may experience dilution if the company secures PIPE financing.
• Employees of the target company may be affected by the business combination.
• Creditors of the company may be impacted if the company is unable to complete the business combination and is forced to liquidate.

Next Steps

• The company needs to complete the business combination with Shanghai Maius Pharmaceutical Technology Co., LTD by the deadline of February 23, 2025, or February 23, 2026, if extended.
• The company needs to obtain the necessary shareholder approvals and regulatory clearances for the business combination.
• The company needs to secure PIPE financing or other alternative financing arrangements.
• The company needs to address the material weaknesses in its internal control over financial reporting.
• The company needs to monitor the impact of economic uncertainty, capital market disruptions, and geopolitical instability on its business.

Key Dates

Keywords

Business Combination, SPAC, IPO, Shanghai Maius Pharmaceutical Technology, Trust Account, Redemption, Going Concern, Financial Statements, Net Income, Private Placement